1
|
Park ES, Choi S, Shin B, Yu J, Yu J, Hwang JM, Yun H, Chung YH, Choi JS, Choi Y, Rho J. Tumor necrosis factor (TNF) receptor-associated factor (TRAF)-interacting protein (TRIP) negatively regulates the TRAF2 ubiquitin-dependent pathway by suppressing the TRAF2- sphingosine 1-phosphate (S1P) interaction. J Biol Chem 2015; 290:9660-73. [PMID: 25716317 DOI: 10.1074/jbc.m114.609685] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2014] [Indexed: 11/06/2022] Open
Abstract
The signaling pathway downstream of TNF receptor (TNFR) is involved in the induction of a wide range of cellular processes, including cell proliferation, activation, differentiation, and apoptosis. TNFR-associated factor 2 (TRAF2) is a key adaptor molecule in TNFR signaling complexes that promotes downstream signaling cascades, such as nuclear factor-κB (NF-κB) and mitogen-activated protein kinase activation. TRAF-interacting protein (TRIP) is a known cellular binding partner of TRAF2 and inhibits TNF-induced NF-κB activation. Recent findings that TRIP plays a multifunctional role in antiviral response, cell proliferation, apoptosis, and embryonic development have increased our interest in exploring how TRIP can affect the TNFR-signaling pathway on a molecular level. In our current study, we demonstrated that TRIP is negatively involved in the TNF-induced inflammatory response through the down-regulation of proinflammatory cytokine production. Here, we demonstrated that the TRAF2-TRIP interaction inhibits Lys(63)-linked TRAF2 ubiquitination by inhibiting TRAF2 E3 ubiquitin (Ub) ligase activity. The TRAF2-TRIP interaction inhibited the binding of sphingosine 1-phosphate, which is a cofactor of TRAF2 E3 Ub ligase, to the TRAF2 RING domain. Finally, we demonstrated that TRIP functions as a negative regulator of proinflammatory cytokine production by inhibiting TNF-induced NF-κB activation. These results indicate that TRIP is an important cellular regulator of the TNF-induced inflammatory response.
Collapse
Affiliation(s)
- Eui-Soon Park
- From the Department of Microbiology and Molecular Biology, Chungnam National University, Daejeon 305-764, Korea
| | - Seunga Choi
- From the Department of Microbiology and Molecular Biology, Chungnam National University, Daejeon 305-764, Korea
| | - Bongjin Shin
- From the Department of Microbiology and Molecular Biology, Chungnam National University, Daejeon 305-764, Korea
| | - Jungeun Yu
- From the Department of Microbiology and Molecular Biology, Chungnam National University, Daejeon 305-764, Korea
| | - Jiyeon Yu
- From the Department of Microbiology and Molecular Biology, Chungnam National University, Daejeon 305-764, Korea
| | - Jung-Me Hwang
- From the Department of Microbiology and Molecular Biology, Chungnam National University, Daejeon 305-764, Korea
| | - Hyeongseok Yun
- From the Department of Microbiology and Molecular Biology, Chungnam National University, Daejeon 305-764, Korea
| | - Young-Ho Chung
- the Division of Life Science, Korea Basic Science Institute, Daejeon 305-333, Korea, and
| | - Jong-Soon Choi
- the Division of Life Science, Korea Basic Science Institute, Daejeon 305-333, Korea, and
| | - Yongwon Choi
- the Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104
| | - Jaerang Rho
- From the Department of Microbiology and Molecular Biology, Chungnam National University, Daejeon 305-764, Korea,
| |
Collapse
|
2
|
Liu M, Allegood J, Zhu X, Seo J, Gebre AK, Boudyguina E, Cheng D, Chuang CC, Shelness GS, Spiegel S, Parks JS. Uncleaved ApoM signal peptide is required for formation of large ApoM/ sphingosine 1-phosphate (S1P)-enriched HDL particles. J Biol Chem 2015; 290:7861-70. [PMID: 25627684 DOI: 10.1074/jbc.m114.631101] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Apolipoprotein M (apoM), a plasma sphingosine 1-phosphate (S1P) carrier, associates with plasma HDL via its uncleaved signal peptide. Hepatocyte-specific apoM overexpression in mice stimulates formation of both larger nascent HDL in hepatocytes and larger mature apoM/S1P-enriched HDL particles in plasma by enhancing hepatic S1P synthesis and secretion. Mutagenesis of apoM glutamine 22 to alanine (apoM(Q22A)) introduces a functional signal peptidase cleavage site. Expression of apoM(Q22A) in ABCA1-expressing HEK293 cells resulted in the formation of smaller nascent HDL particles compared with wild type apoM (apoM(WT)). When apoM(Q22A) was expressed in vivo, using recombinant adenoviruses, smaller plasma HDL particles and decreased plasma S1P and apoM were observed relative to expression of apoM(WT). Hepatocytes isolated from both apoM(WT)- and apoM(Q22A)-expressing mice displayed an equivalent increase in cellular levels of S1P, relative to LacZ controls; however, relative to apoM(WT), apoM(Q22A) hepatocytes displayed more rapid apoM and S1P secretion but minimal apoM(Q22A) bound to nascent lipoproteins. Pharmacologic inhibition of ceramide synthesis increased cellular sphingosine and S1P but not medium S1P in both apoM(WT) and apoM(Q22A) hepatocytes. We conclude that apoM secretion is rate-limiting for hepatocyte S1P secretion and that its uncleaved signal peptide delays apoM trafficking out of the cell, promoting formation of larger nascent apoM- and S1P-enriched HDL particles that are probably precursors of larger apoM/S1P-enriched plasma HDL.
Collapse
Affiliation(s)
- Mingxia Liu
- From the Department of Internal Medicine, Section on Molecular Medicine, and
| | - Jeremy Allegood
- the Department of Biochemistry and Molecular Biology, Virginia Commonwealth University School of Medicine, Richmond, Virginia 23298
| | - Xuewei Zhu
- From the Department of Internal Medicine, Section on Molecular Medicine, and
| | - Jeongmin Seo
- From the Department of Internal Medicine, Section on Molecular Medicine, and
| | - Abraham K Gebre
- From the Department of Internal Medicine, Section on Molecular Medicine, and
| | - Elena Boudyguina
- From the Department of Internal Medicine, Section on Molecular Medicine, and
| | - Dongmei Cheng
- From the Department of Internal Medicine, Section on Molecular Medicine, and
| | - Chia-Chi Chuang
- From the Department of Internal Medicine, Section on Molecular Medicine, and
| | - Gregory S Shelness
- From the Department of Internal Medicine, Section on Molecular Medicine, and the Department of Biochemistry, Wake Forest School of Medicine, Winston-Salem, North Carolina 27157 and
| | - Sarah Spiegel
- the Department of Biochemistry and Molecular Biology, Virginia Commonwealth University School of Medicine, Richmond, Virginia 23298
| | - John S Parks
- From the Department of Internal Medicine, Section on Molecular Medicine, and the Department of Biochemistry, Wake Forest School of Medicine, Winston-Salem, North Carolina 27157 and
| |
Collapse
|
3
|
Kurano M, Tsukamoto K, Hara M, Ohkawa R, Ikeda H, Yatomi Y. LDL receptor and ApoE are involved in the clearance of ApoM-associated sphingosine 1-phosphate. J Biol Chem 2014; 290:2477-88. [PMID: 25505264 DOI: 10.1074/jbc.m114.596445] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023] Open
Abstract
Sphingosine 1-phosphate (S1P) is a vasoactive lipid mediator that is speculated to be involved in various aspects of atherosclerosis. About 70% of circulating plasma S1P is carried on HDL, and several pleiotropic properties of HDL have been ascribed to S1P. In the previous study with human subjects, however, LDL cholesterol or apoB, but not HDL cholesterol or apoA-I, had a significant positive correlation with the plasma S1P level, suggesting that the metabolic pathway for LDL might have some roles in the metabolism of S1P. In this study, we analyzed the association between LDL receptor, an important protein in the clearance of LDL, and circulating S1P. We observed that in LDL receptor-overexpressing mice, the plasma S1P levels as well as apolipoprotein M (apoM), a carrier of S1P, were decreased and that exogenously administered C17S1P bound to apoM-containing lipoproteins was cleared more rapidly. Unlike the situation in wild-type mice, LDL receptor overexpression in apoE-deficient mice did not reduce the plasma S1P or apoM levels, suggesting that apoE might be a ligand for the LDL receptor during the clearance of these factors. The present findings clarify the novel roles of the LDL receptor and apoE in the clearance of S1P, a multifunctional bioactive phospholipid.
Collapse
Affiliation(s)
- Makoto Kurano
- From the Department of Clinical Laboratory Medicine, Graduate School of Medicine, University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-8655
| | - Kazuhisa Tsukamoto
- the Department of Metabolism, Diabetes and Nephrology, Aizu Medical Center, Fukushima Medical University, 21-2, Maeda, Yazawaji, Higashimachi, Aizuwakamatsu, Fukushima 969-3482
| | - Masumi Hara
- the Department of Medicine IV, Mizonokuchi Hospital, Teikyo University School of Medicine, 3-8-3, Mizonokuchi, Takatsu-ku, Kawasaki, Kanagawa 213-0001, Japan
| | - Ryunosuke Ohkawa
- the Department of Clinical Laboratory, University of Tokyo Hospital, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-8655, and
| | - Hitoshi Ikeda
- From the Department of Clinical Laboratory Medicine, Graduate School of Medicine, University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-8655, the Department of Clinical Laboratory, University of Tokyo Hospital, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-8655, and
| | - Yutaka Yatomi
- From the Department of Clinical Laboratory Medicine, Graduate School of Medicine, University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-8655, the Department of Clinical Laboratory, University of Tokyo Hospital, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-8655, and
| |
Collapse
|
4
|
Wakashima T, Abe K, Kihara A. Dual functions of the trans-2-enoyl-CoA reductase TER in the sphingosine 1-phosphate metabolic pathway and in fatty acid elongation. J Biol Chem 2014; 289:24736-48. [PMID: 25049234 DOI: 10.1074/jbc.m114.571869] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
The sphingolipid metabolite sphingosine 1-phosphate (S1P) functions as a lipid mediator and as a key intermediate of the sole sphingolipid to glycerophospholipid metabolic pathway (S1P metabolic pathway). In this pathway, S1P is converted to palmitoyl-CoA through 4 reactions, then incorporated mainly into glycerophospholipids. Although most of the genes responsible for the S1P metabolic pathway have been identified, the gene encoding the trans-2-enoyl-CoA reductase, responsible for the saturation step (conversion of trans-2-hexadecenoyl-CoA to palmitoyl-CoA) remains unidentified. In the present study, we show that TER is the missing gene in mammals using analyses involving yeast cells, deleting the TER homolog TSC13, and TER-knockdown HeLa cells. TER is known to be involved in the production of very long-chain fatty acids (VLCFAs). A significant proportion of the saturated and monounsaturated VLCFAs are used for sphingolipid synthesis. Therefore, TER is involved in both the production of VLCFAs used in the fatty acid moiety of sphingolipids as well as in the degradation of the sphingosine moiety of sphingolipids via S1P.
Collapse
Affiliation(s)
- Takeshi Wakashima
- From the Laboratory of Biochemistry, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12-jo, Nishi 6-chome, Kita-ku, Sapporo 060-0812, Japan
| | - Kensuke Abe
- From the Laboratory of Biochemistry, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12-jo, Nishi 6-chome, Kita-ku, Sapporo 060-0812, Japan
| | - Akio Kihara
- From the Laboratory of Biochemistry, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12-jo, Nishi 6-chome, Kita-ku, Sapporo 060-0812, Japan
| |
Collapse
|